# Eloralintide vs Cagrilintide: Amylin Agonists Compared
> Note: PeptIQ is not a medical provider. Both compounds discussed here have investigational or regulatory-status nuances. This is educational comparison content, not prescribing guidance.
Search interest in eloralintide vs cagrilintide is rising for the same reason "retatrutide vs tirzepatide" exploded: people want the pathway map. Both molecules sit in the amylin lane of obesity pharmacology — but they are not the same drug, not the same development story, and not interchangeable milligram-for-milligram.
The One-Sentence Difference
- Eloralintide (LY3841136): Eli Lilly's investigational selective amylin receptor agonist, developed as once-weekly therapy with strong Phase 2 monotherapy weight-loss data and a Phase 3 ENLIGHTEN program.
- Cagrilintide: Novo Nordisk's long-acting amylin analogue, best known as the amylin component of CagriSema (cagrilintide + semaglutide).
Shared idea: amylin pathway satiety. Different sponsors, different molecules, different combo strategies.
Side-by-Side Comparison
| Eloralintide | Cagrilintide | |
|---|---|---|
| Sponsor story | Lilly (LY3841136) | Novo (CagriSema partner molecule) |
| Biology framing | Selective amylin receptor agonist | Long-acting amylin analogue |
| Best-known use case | Monotherapy obesity program + incretin combo studies | Combo with semaglutide (CagriSema); also studied alone |
| Cadence in key trials | Once weekly SC | Once weekly SC (in CagriSema) |
| Standout public efficacy signal | Phase 2: ~9–20% mean weight loss at 48 weeks across dose arms | REDEFINE 1: combo ~20%+; cagrilintide alone mid-teens % range depending on analysis |
| Strategic role | Lilly's amylin entry beside tirzepatide / retatrutide / orforglipron | Novo's amylin + GLP-1 pairing strategy |
Mechanism: Same Neighborhood, Different Addresses
Amylin helps end meals earlier and slows gastric emptying. GLP-1 does related appetite work through incretin receptors. That overlap is why combinations look attractive — and why side-effect profiles can still feel "GLP-1-like" (nausea, fullness) even when the primary label is amylin.
Eloralintide is positioned as a selective amylin agonist: the clinical bet is strong satiety with a monotherapy path, plus optional pairing with incretins for people who still have residual obesity on a weekly GLP-1/GIP drug.
Cagrilintide became famous because alone it was good, but with semaglutide it was better in Phase 3 obesity readouts. The lesson from CagriSema is combinatorial: amylin + GLP-1 can beat either alone.
Dosing Context (Not Cross-Titration)
| Program | Public dose anchors |
|---|---|
| Eloralintide Phase 2 | 1, 3, 6, 9 mg weekly; escalations to 9 mg |
| CagriSema (REDEFINE 1) | Cagrilintide 2.4 mg + semaglutide 2.4 mg weekly |
Do not convert "9 mg eloralintide" into "2.4 mg cagrilintide." Receptor selectivity, exposure, and formulation differ.
Which One "Wins"?
Wrong question for 2026. Better questions:
